CV Therapeutics to Announce Third Quarter Financial Results on Tuesday, October 31, 2006
October 17 2006 - 7:01PM
PR Newswire (US)
PALO ALTO, Calif., Oct. 17 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) today announced that it will
release third quarter financial results for 2006 after the market
closes on Tuesday, October 31, 2006. Company management will
webcast a conference call at 5:00 p.m. EST, 2:00 p.m. PST, on the
Company's website. To access the live webcast, please log on to the
Company's website at http://www.cvt.com/ and go to the Investor
Information section. Alternatively, domestic callers may
participate in the conference call by dialing (888) 370-6121, and
international callers may participate in the conference call by
dialing (706) 679-7163. Webcast and telephone replays of the
conference call will be available approximately two hours after the
completion of the call through Tuesday, November 07, 2006. Domestic
callers can access the replay by dialing (800) 642-1687, and
international callers can access the replay by dialing (706)
645-9291; the PIN access number is 8804902. About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company focused on applying molecular cardiology
to the discovery, development and commercialization of novel, small
molecule drugs for the treatment of cardiovascular diseases. CV
Therapeutics' approved product, Ranexa(R) (ranolazine
extended-release tablets) is indicated for the treatment of chronic
angina in patients who have not achieved an adequate response with
other antianginal drugs, and should be used in combination with
amlodipine, beta-blockers or nitrates. CV Therapeutics also has
other clinical and preclinical drug development candidates and
programs, including regadenoson, which is being developed for
potential use as a pharmacologic stress agent in myocardial
perfusion imaging studies and CVT-6883, which is being developed as
a potential treatment for asthma and other conditions. Regadenoson
and CVT-6883 have not been determined by any regulatory authorities
to be safe or effective in humans for any use. DATASOURCE: CV
Therapeutics, Inc. CONTACT: investors and media, John Bluth, Senior
Director, Corporate Communications & Investor Relations of CV
Therapeutics, Inc., +1-650-384-8850 Web site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024